Join us to build the future of drug discovery at Tahoe Therapeutics (South San Francisco, CA)

Tahoe Therapeutics· South San Francisco, CA·2d ago

Role details

Work type

Hybrid

Job description

Our team is continuously growing with strong scientists and engineers. If you are excited about what we are building at Tahoe and think you have unique talents that can help us with that, please apply by clicking below and include a resume/cv, along with a cover letter that explains the type of roles you'd be interested in.

We are particularly interested in people with solid backgrounds in:

-Single-cell bioinformatics on large atlas datasets -Machine learning applied to genomics data and cheminformatics -High throughput synthetic lethal oncology genomics screens and subsequent target validation of individual genes -Junior Scientists with tissue culture, single-cell sample preparation, laboratory automation using robotics, and biochemical assays for target validation and mechanistic investigation -Medicinal chemistry, particularly in small molecule oncology

Please note this job description is not designed to cover or contain a comprehensive listing of activities, duties or responsibilities that are required of the employee for this job. Duties, responsibilities, and activities may change at any time with or without notice.

Why work at Tahoe Therapeutics

Culture: "We are not content with incrementalism. We make big bets and work hard to make sure they happen." Team is dynamic, mission-driven, and focused on high-impact science.
Work model: Roles are primarily on-site in South San Francisco, with some hybrid opportunities (e.g., drug discovery roles). Current openings include Senior/Staff Full-Stack Engineer, Senior Machine Learning Engineer, Senior Machine Learning Scientist, and Research Associate.
Perks & environment: Inaugural hackathon for building on Tahoe-100M; exposure to cutting-edge AI + biotech; collaboration with top academic and industry partners; strong growth trajectory with a 40% headcount increase and expanding job postings.
Caveat: Employer rating is 2.3/5 based on 9 reviews (culture 2.0, career 2.1, compensation 2.9, work-life 3.5) — a small sample that may not reflect the current evolving environment.

About Tahoe Therapeutics

Company Overview

One-liner: Tahoe Therapeutics builds the ground truth for biological superintelligence by generating large-scale perturbative single-cell data and training AI models to predict cellular responses, transforming drug discovery.
Entity Type: Private (Series A)
Headquarters: South San Francisco, California, USA
Founded: 2022 (formerly Vevo Therapeutics)
Founders: Nima Alidoust (CEO & Cofounder), Johnny Yu (CSO & Cofounder), Hani Goodarzi (Cofounder)

Core Business

Primary industry: Biotechnology / AI-powered drug discovery
Target customers: Biopharmaceutical companies, research institutions, and drug discovery partners
Mission/purpose: To build the ground truth for biological superintelligence — generating in vivo data at scale and training AI models to discover better drugs for more patients, including targets previously considered "undruggable."

Products & Services

Mosaic Platform: Proprietary in vivo drug discovery platform that generates perturbative single-cell data at scale and single-cell precision across primary cells, organoids, iPSC-derived cells, and in vivo models with immune context.
Rhaister: A machine learning model for drug response prediction that learns from Tahoe's generated data and creates synthetic data for new biological contexts — trained in seconds, running in milliseconds.
Tara: An autonomous research agent that traverses Tahoe's data ocean, generates hypotheses, validates them, and surfaces discoveries rather than guesses.
Tahoe-100M: The world's largest open-source single-cell dataset, released as the inaugural contribution to Arc Institute's Virtual Cell Atlas.

Market Standing

Valuation/Market Cap: Not disclosed (private company)
Key Metric: Total funding of $72M across three rounds (Seed $12M in 2022; two Series A rounds of $30M each in 2025)
Notable Investors/Partners: Wing Venture Capital, General Catalyst, Amplify Partners; partners include Parse Biosciences GigaLab, Arc Institute, and Alloy Therapeutics (joint venture for antibody-drug conjugates)
Growth Signals: Headcount grew ~40% YoY to ~29 employees; active job postings up 400% YoY; published the GENEVA platform in Nature Cancer (2026); released Rhaister (2026); formed ADC joint venture with Alloy Therapeutics (2026); open-sourced Tahoe-100M dataset (2025)

Competitive Advantages

Proprietary data flywheel: Mosaic generates in vivo single-cell perturbation data at a scale and diversity competitors cannot easily replicate, feeding AI models that improve with each dataset.
Open-source leadership: Tahoe-100M is the largest open single-cell dataset, establishing the company as a standard-setter in the virtual cell atlas space.
World-class team: Founders and leadership have discovered drugs for undruggable targets, trained frontier AI models on chemical/biological data, and invented novel methods in single-cell and cancer biology.
Integrated verification loop: Tara closes the loop between hypothesis generation and validation, reducing reliance on guesses and accelerating discovery.

Strategic Focus

Scaling the world's largest in vivo atlas of how drugs interact with patient cells.
Advancing AI models (Rhaister and successors) for drug response prediction and synthetic data generation.
Expanding therapeutic partnerships, including the Alloy Therapeutics joint venture for first-in-class antibody-drug conjugates.
Growing the team across machine learning, research, and drug discovery to support platform development and pipeline advancement.

Sources

Job description

Why work at Tahoe Therapeutics

Application questions